Enalapril improves obesity associated liver injury ameliorating systemic metabolic markers by modulating Angiotensin Converting Enzymes ACE/ACE2 expression in high-fat feed mice
Related Experiment Video
Updated: Dec 6, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
Daniel Silva Moraes1, Deborah de Farias Lelis1, João Marcus Oliveira Andrade1
1Laboratory of Health Science, Postgraduate Program in Health Sciences, Universidade Estadual de Montes Claros (UNIMONTES), Montes Claros, Minas Gerais, Brazil.
Abstract:
Obesity is a chronic disease caused multiple associated factors that results in excessive body fat accumulation. The Renin-Angiotensin System (RAS) unbalance is now recognized as a key factor on regulating body energy and metabolism.
Aim:
The aim of the present study was to evaluate the Enalapril (ACE inhibitor) effects on the metabolic function and hepatic steatosis of obese mice evaluating Angiotensin Converting Enzymes (ACEs) expression.
Methods:
The experiment was performed using 32 male Swiss mice (8 weeks old) equally and randomly divided into 4 groups (n = 8): standard diet (ST), standard diet plus Enalapril (ST + ENAL), hyperlipidic diet (HF) and hyperlipidic diet plus Enalapril (HF + ENAL). Weekly measurements of animal weight and feed consumption were performed. At the end of treatment period a glucose tolerance test (GTT) and insulin sensitivity test (IST) were performed. Ultrasonography was used to evaluate hepatic and epididymal fat pad. Liver samples were submitted to HE histology and gene expression analyses were performed using Real-Time PCR.
Results:
The main results showed a decrease in body weight after treatment with Enalapril, as well as a reduced size of epididymal fat pad (EFP). Hepatic echogenicity and steatosis measurement were lower in the obese groups treated with Enalapril also modulating ACE2/ACE expressions.
Conclusions:
Enalapril use improved metabolism reducing hepatic steatosis, decreasing ACE expression and increasing ACE2 expression.
Insights
Enalapril treatment reduced body weight and hepatic steatosis in obese mice by modulating the Renin-Angiotensin System (RAS). This study highlights Enalapril
Area of Science:
- Metabolic disorders
- Obesity research
- Pharmacology
Background:
- Obesity is a chronic disease linked to Renin-Angiotensin System (RAS) imbalance.
- RAS dysregulation affects body energy and metabolism.
Purpose of the Study:
- Evaluate Enalapril's effects on metabolic function and hepatic steatosis in obese mice.
- Assess Enalapril's impact on Angiotensin Converting Enzymes (ACEs) expression.
Main Methods:
- 32 male Swiss mice divided into standard diet, standard diet + Enalapril, hyperlipidic diet, and hyperlipidic diet + Enalapril groups.
- Weekly monitoring of weight and feed intake; glucose tolerance and insulin sensitivity tests.
- Ultrasonography for fat pad evaluation; liver histology and gene expression analysis (Real-Time PCR).
Main Results:
- Enalapril treatment decreased body weight and epididymal fat pad size.
- Reduced hepatic echogenicity and steatosis in obese mice treated with Enalapril.
- Modulation of Angiotensin Converting Enzyme 2 (ACE2)/Angiotensin Converting Enzyme (ACE) expressions observed.
Conclusions:
- Enalapril improved metabolic function and reduced hepatic steatosis in obese mice.
- Enalapril decreased ACE expression and increased ACE2 expression, suggesting a role in RAS balance.
- Enalapril demonstrates therapeutic potential for obesity-related metabolic dysfunction.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Atherosclerosis III: Management

